Dexcom (DXCM) Cost of Revenue (2010 - 2026)

Dexcom (DXCM) has 17 years of Cost of Revenue data on file, last reported at $441.6 million in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $441.6 million, down 1.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 billion (up 10.22% YoY), and the FY2025 annual result was $1.9 billion, up 16.64% from the prior year.
• Cost of Revenue eased to $441.6 million in Q1 2026 per DXCM's latest filing, from $466.9 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $477.9 million in Q3 2025 and troughed at $230.7 million in Q1 2022.
• A 5-year average of $368.0 million and a median of $377.6 million in 2024 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2022 and 2026: Cost of Revenue surged 43.2% in 2022, then declined 1.21% in 2026.
• A 5-year view of Cost of Revenue shows it stood at $273.9 million in 2022, then soared by 37.97% to $377.9 million in 2023, then grew by 21.12% to $457.7 million in 2024, then grew by 2.01% to $466.9 million in 2025, then fell by 5.42% to $441.6 million in 2026.
• Business Quant data shows DXCM's Cost of Revenue at $441.6 million in Q1 2026, $466.9 million in Q4 2025, and $477.9 million in Q3 2025.